Femasys Inc. FEMY
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -88.11%
- 1 year
- -91.23%
- Market cap
- 11.47M
- Revenue (ttm)
- 950.10K
- EPS (ttm)
- -3.28
- Shares out
- 22.90M
- Forward P/E
- -2.33
- YTD return
- -88.11%
- 1-year return
- -91.23%
- Volume
- 72.72K
- Avg volume
- 741.04K
- Open
- 1.32
- Previous close
- 1.31
- Day's range
- 1.30 – 1.41
- 52-week range
- 1.31 – 20.80
- Beta
- -2.83
- Price target
- 8.25 (+502.2%)
- Earnings date
- Aug 8, 2024
5D +0.03 (+2.24%)
Key statistics
- Enterprise value
- 16.44M
- PEG ratio
- 0.00
- Price / sales
- 25.79
- Price / book
- 1.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -30.90%
- Free cash flow
- -9.24M
- Total cash
- 13.53M
- Total debt
- 7.06M
- Return on equity
- -138.37%
- Short % of float
- 3.01%
- 50-day average
- 1.14
- 200-day average
- 1.22
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 8.25
- Target (high)
- 12.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.18.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.20 | -0.24 | -0.04 | -20.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.18 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.18 | -0.21 | -0.03 | -16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.22 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.22 | -0.17 | +0.05 | +22.73% |
| Mar 28, 2024 | Dec 1, 2023 | -0.19 | -0.19 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Femasys Inc.
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- femasys.com
News
Femasys Doubles Number Of Enrolling Facilities To 12 In Its FemBloc FINALE Pivotal Study Across U.S. 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Femasys Files Prospectus Related To The Offer And Resale From Time To Time By The Selling Stockholders Of Up To An Aggregate Of 28,124,997 Shares Of Common Stock 
12 Health Care Stocks Moving In Friday's Intraday Session 
Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations 
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate
- Maxim Group Maintains Buy on Femasys, Lowers Price Target to $10
Your note
Sign in to keep a note on FEMY — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| CM Management, LLC | 1.86% | 425,000 | 454.75K | Sep 29, 2024 |
| Clear Creek Financial Management, LLC | 1.34% | 306,624 | 328.09K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.90% | 206,483 | 220.94K | Sep 29, 2024 |
| Vanguard Group Inc | 0.84% | 192,667 | 206.15K | Sep 29, 2024 |
| Northern Trust Corporation | 0.39% | 88,421 | 94.61K | Sep 29, 2024 |
| State Street Corporation | 0.25% | 56,369 | 60.31K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.84% | 192,667 | 206.15K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 114,169 | 122.16K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 34,093 | 36.48K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 27,036 | 28.93K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.08% | 18,182 | 19.45K | Oct 30, 2024 |